Oral Side Effects of COVID-19 Vaccine

NCT ID: NCT04706156

Last Updated: 2021-02-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1540 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-27

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter cross-sectional survey-based study conducted in four European countries (Czech Republic, Germany, Slovak Republic, and Turkey). An online questionnaire will be utilized to collect data from volunteer subjects following the STROBE reporting guidelines of cross-sectional studies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this multicentre cross-sectional survey-based study is to estimate the prevalence of oral side effects of COVID-19 vaccine in the short term.

The secondary objectives are:

* to identify the risk factors of COVID-19 vaccine oral side effects in the short term.
* to evaluate the relationship between oral side effects and other inflammatory side effects of COVID-19 vaccine in the short term.

The target population is healthcare workers as they are identified among the priority groups of COVID-19 vaccine deployment plans in the EU/EEA and the UK. One more reason to select the healthcare workers among different groups of the population, their higher awareness about the possible vaccine-related oral side-effects so that more accurate and reliable results can be obtained.

A self-administered questionnaire will be developed, and its content validity will be tested using a panel of experts. The test re-test reliability of the questionnaire will be tested by 30 volunteers (10 Czech, 10 Turkish, 10 German) to achieve at least a Cronbach's alpha of 0.70. The questionnaire will be available in five languages; Czech, English, German, Slovak and Turkish. Dual forward translation and expert panels will produce equivalent Czech, German, Slovak and Turkish versions of the questionnaire.

The questionnaire will be composed of multiple-choice items divided into four main categories; a) demographic data including gender, age, location of practice, profession, and experience, b) medical anamnesis including medical comorbidities, medications, and recent oral symptoms, c) COVID-19 related anamnesis including vaccination date, previous infection, and exposure to infected cases, and d) vaccine side effects including inflammatory symptoms, cutaneous symptoms, and oral symptoms. (Annex 1)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Manifestations Covid19 Vaccine Adverse Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated Healthcare Workers (CZ)

Czech healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)

COVID-19 Vaccine

Intervention Type BIOLOGICAL

Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Vaccinated Healthcare Workers (DE)

German healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)

COVID-19 Vaccine

Intervention Type BIOLOGICAL

Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Vaccinated Healthcare Workers (SK)

Slovak healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)

COVID-19 Vaccine

Intervention Type BIOLOGICAL

Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Vaccinated Healthcare Workers (TR)

Turkish healthcare workers who received COVID-19 vaccine during the last 30 days (n=385)

COVID-19 Vaccine

Intervention Type BIOLOGICAL

Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 Vaccine

Receiving coronavirus disease (COVID-19) vaccine e.g. Pfizer-BioNTech, Moderna, Oxford/AstraZeneca, or Sinovac COVID-19 Vaccine

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthcare workers who received COVID-19 vaccine during the last 30 days.
* Participating subjects should be at least 18-year-old and able to give their informed consent independently.

Exclusion Criteria

* The healthcare workers who did not receive the COVID-19 vaccine recently.
* Non-healthcare workers who received the COVID-19 vaccine recently.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

OTHER

Sponsor Role collaborator

University of Giessen

OTHER

Sponsor Role collaborator

University of Kiel

OTHER

Sponsor Role collaborator

Yeditepe University

OTHER

Sponsor Role collaborator

Masaryk University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Abanoub Riad, DDS

Role: PRINCIPAL_INVESTIGATOR

Masaryk University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Public Health, Faculty of Medicine, Masaryk University

Brno, South-Moravia, Czechia

Site Status RECRUITING

Department of Cranio-Maxillofacial Surgery, Justus-Liebig University Giessen

Giessen, Hesse, Germany

Site Status RECRUITING

Clinic for Conservative Dentistry and Periodontology, School of Dental Medicine, Christian-Albrecht's University

Kiel, Schleswig-Holstein, Germany

Site Status RECRUITING

Department of Maxillofacial Surgery, F. D. Roosevelt University Hospital

Banská Bystrica, Banská Bystrica Region, Slovakia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Czechia Germany Slovakia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Abanoub Riad, DDS

Role: CONTACT

+420721046024

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Abanoub Riad, DDS

Role: primary

+420 549 49 6572

Michal Koscik, PhD

Role: backup

+420 549 49 1324

Sameh Attia, DDS

Role: primary

Jonas Conrad, DDS

Role: primary

Mohamed Mekhemar, DDS

Role: backup

Barbora Hocková, DDS

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Riad A, Klugar M, Krsek M. COVID-19-Related Oral Manifestations: Early Disease Features? Oral Dis. 2022 Apr;28 Suppl 1(Suppl 1):940-942. doi: 10.1111/odi.13516. Epub 2020 Jul 16. No abstract available.

Reference Type BACKGROUND
PMID: 32603497 (View on PubMed)

Riad A, Gad A, Hockova B, Klugar M. Oral candidiasis in non-severe COVID-19 patients: call for antibiotic stewardship. Oral Surg. 2022 Aug;15(3):465-466. doi: 10.1111/ors.12561. Epub 2020 Oct 9. No abstract available.

Reference Type BACKGROUND
PMID: 33042219 (View on PubMed)

Riad A, Kassem I, Stanek J, Badrah M, Klugarova J, Klugar M. Aphthous stomatitis in COVID-19 patients: Case-series and literature review. Dermatol Ther. 2021 Jan;34(1):e14735. doi: 10.1111/dth.14735. Epub 2021 Jan 10. No abstract available.

Reference Type BACKGROUND
PMID: 33389769 (View on PubMed)

Riad A, Kassem I, Hockova B, Badrah M, Klugar M. Halitosis in COVID-19 patients. Spec Care Dentist. 2021 Mar;41(2):282-285. doi: 10.1111/scd.12547. Epub 2020 Nov 29. No abstract available.

Reference Type BACKGROUND
PMID: 33249615 (View on PubMed)

Riad A, Kassem I, Badrah M, Klugar M. The manifestation of oral mucositis in COVID-19 patients: A case-series. Dermatol Ther. 2020 Nov;33(6):e14479. doi: 10.1111/dth.14479. Epub 2020 Nov 8. No abstract available.

Reference Type BACKGROUND
PMID: 33125803 (View on PubMed)

Riad A, Kassem I, Issa J, Badrah M, Klugar M. Angular cheilitis of COVID-19 patients: A case-series and literature review. Oral Dis. 2022 Apr;28 Suppl 1(Suppl 1):999-1000. doi: 10.1111/odi.13675. Epub 2020 Oct 23. No abstract available.

Reference Type BACKGROUND
PMID: 33043573 (View on PubMed)

Riad A, Kassem I, Hockova B, Badrah M, Klugar M. Tongue ulcers associated with SARS-CoV-2 infection: A case series. Oral Dis. 2022 Apr;28 Suppl 1:988-990. doi: 10.1111/odi.13635. Epub 2020 Sep 25. No abstract available.

Reference Type BACKGROUND
PMID: 32889763 (View on PubMed)

Riad A, Kassem I, Badrah M, Klugar M. Acute parotitis as a presentation of COVID-19? Oral Dis. 2022 Apr;28 Suppl 1:968-969. doi: 10.1111/odi.13571. Epub 2020 Aug 6. No abstract available.

Reference Type BACKGROUND
PMID: 32713097 (View on PubMed)

Riad A, Kassem I, Badrah M, Klugar M. COVID-19 transient snoring (CVTS): Clinical and laboratory description. J Med Virol. 2021 Apr;93(4):1890-1892. doi: 10.1002/jmv.26705. Epub 2020 Dec 17. No abstract available.

Reference Type BACKGROUND
PMID: 33289127 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OSECV

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

GEL & MEDication Dysphagia
NCT07254663 RECRUITING